Macro trends in pharmaceutical innovation

被引：70

作者：

Cohen, FJ ^{[1
]}

机构：

[1] Crownstone, Bensalem, PA 19020 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2005年 / 4卷 / 01期

关键词：

D O I：

10.1038/nrd1610

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Critics decry the lack of 'truly innovative' new medicines and question the role of the pharmaceutical industry in creating the few that are developed. Is this an accurate portrayal of the state of pharmaceutical innovation? Does major pharma still innovate? If so, how? Must the industry innovate to survive? These and related issues are discussed.

引用

页码：78 / 84

页数：7

共 26 条

[1] BENASHER D, 1999, 270 HARV LAW SCH
[2] BOOTH BL, 2004, MCKINSEY Q, V4
[3] *CTR DRUG EV RES, 2003, REP NAT 2003 IMPR PU
[4] *FTC, PROM INN PROP BAL CO
[5] Grab A, 2003, J MOD ITAL STUD, V8, P104
[6] Returns on research and development for 1990s new drug introductions
Grabowski, H
Vernon, J
DiMasi, JA
[J]. PHARMACOECONOMICS, 2002, 20 (Suppl 3) : 11 - 29
[7] GRABOWSKI Henry John M.VERNON, 1996, COMPETITIVE STRATEGI, P194
[8] MATHIEU MP, PAREXELS R D STAT SO
[9] How does innovative activity change as industries mature?
McGahan, AM
Silverman, BS
[J]. INTERNATIONAL JOURNAL OF INDUSTRIAL ORGANIZATION, 2001, 19 (07) : 1141 - 1160
[10] *NAT RES COUNC, 1996, PROSP NAT KNOWL ASS

← 1 2 3 →